(2 references)-
- 抗原 See all HLA B7 抗体
- HLA B7 (HLA Class I B7 Alpha (HLA B7))
-
适用
- 人, Cynomolgus
-
宿主
- 小鼠
-
克隆类型
- 单克隆
-
标记
- This HLA B7 antibody is un-conjugated
-
应用范围
- Flow Cytometry (FACS)
- 交叉反应
- Cynomolgus
- 产品特性
- Purified IgG
- 纯化方法
- Purified
- 免疫原
- Papain solubilized HLA-B7 antigen
- 克隆位点
- BB7-1
- 亚型
- IgG1
- Top Product
- Discover our top product HLA B7 Primary Antibody
-
anti-HLA Class I B7 Alpha (HLA B7) antibody (PE)
HLA B7 适用: 人, Non-Human Primate FACS 宿主: 小鼠 Monoclonal BB7-1 PE
anti-HLA Class I B7 Alpha (HLA B7) antibodyHLA B7 适用: 人, Non-Human Primate FACS 宿主: 小鼠 Monoclonal BB7-1 unconjugated
anti-HLA Class I B7 Alpha (HLA B7) antibody (PE)HLA B7 适用: 人, Cynomolgus FACS 宿主: 小鼠 Monoclonal BB7-1 PE
anti-HLA Class I B7 Alpha (HLA B7) antibody (FITC)HLA B7 适用: 人, Cynomolgus FACS 宿主: 小鼠 Monoclonal BB7-1 FITC
anti-HLA Class I B7 Alpha (HLA B7) antibodyHLA B7 适用: 人, Cynomolgus FACS 宿主: 小鼠 Monoclonal BB7-1 unconjugated
anti-HLA Class I B7 Alpha (HLA B7) (N-Term) antibodyHLA B7 适用: 人 WB, EIA 宿主: 兔 Polyclonal unconjugated
-
- 应用备注
- Optimal working dilution should be determined by the investigator.
- 限制
- 仅限研究用
-
- 状态
- Liquid
- 浓度
- 1.0 mg/mL
-
-
: "Palmitoylation of MIR2 is required for its function." in: Journal of virology, Vol. 85, Issue 5, pp. 2288-95, (2011) (PubMed).
: "Upgrading of flow cytometric analysis for absolute counts, cytokines and other antigenic molecules of cynomolgus monkeys (Macaca fascicularis) by using anti-human cross-reactive antibodies." in: Experimental animals / Japanese Association for Laboratory Animal Science, Vol. 49, Issue 2, pp. 97-110, (2000) (PubMed).
-
: "Palmitoylation of MIR2 is required for its function." in: Journal of virology, Vol. 85, Issue 5, pp. 2288-95, (2011) (PubMed).
-
- 抗原
- HLA B7 (HLA Class I B7 Alpha (HLA B7))
- 别名
- HLA B7 (HLA B7 产品)
- 别名
- AS antibody, HLAB antibody, SPDA1 antibody, major histocompatibility complex, class I, B antibody, HLA-B antibody
- 基因ID
- 3106
- UniProt
- P01889
- 途径
- Human Leukocyte Antigen (HLA) in Adaptive Immune Response
-
You are here:
